ConvaTec earnings outlook draws Bernstein attention, shares trade steadily in London

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 12:39.

ConvaTec (GB00BD3VFW73) enters mid-2026 with a defined earnings narrative. Bernstein sees the UK-listed medical products group’s revenue and profit profile skewed toward the second half of the year, based on margin expansion expectations in core devices. Finimize summary of Bernstein’s view

What Bernstein expects for H2

According to Bernstein, ConvaTec’s adjusted operating profit margin, or EBITA margin, is projected to improve meaningfully in the second half of 2026. The analysts expect the margin to rise to about 25.1 percent in H2, compared with roughly 20.9 percent in H1, reflecting tighter operating expense control and a stronger product mix in Infusion Devices. MarketScreener note on Bernstein’s estimates

Bernstein describes ConvaTec’s 2026 story as a second-half one, with both revenue momentum and profitability expected to gain traction later in the year. The firm points to anticipated operational discipline and mix improvements in infusion-related therapies as key drivers for the margin expansion. Finimize summary of Bernstein’s view

Analyst stance and valuation context

Bernstein maintains a price target of 2.75 pounds sterling for ConvaTec shares, signaling confidence in the group’s ability to deliver the projected second-half earnings acceleration. The analysts consider the current valuation of roughly 13 times earnings as an opportunity, conditioned on the timing and realization of the expected H2 pickup in margins and profits. Finimize summary of Bernstein’s view

ConvaTec’s shares trade on the London Stock Exchange, alongside other medical technology peers, with investors weighing Bernstein’s margin forecasts against broader sector dynamics. The emphasis on earnings acceleration places ConvaTec in an analyst discourse shaped by profitability, capital allocation and execution in its core segments. MarketScreener note on Bernstein’s estimates

The therapies behind the stock

ConvaTec generates revenue from advanced medical products, including infusion therapy systems for chronic conditions such as Parkinson’s disease. The group has secured FDA approval for a Parkinson’s treatment infusion technology, adding to its portfolio alongside wound care, ostomy care and continence management solutions aimed at long-term patient support. MarketScreener note referencing infusion tech approval

Where the shares trade today

The ConvaTec shares (GB00BD3VFW73) trade on the London Stock Exchange at 212.50 pence as of 2026-06-29, 10:30 London time, based on recent data from MarketScreener. MarketScreener price overview

This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any financial instrument. Data and assessments are based on sources believed to be reliable but cannot be guaranteed for accuracy or completeness.